CN102438601A - Electrostatically charged multifunctional nasal applications, products and methods - Google Patents
Electrostatically charged multifunctional nasal applications, products and methods Download PDFInfo
- Publication number
- CN102438601A CN102438601A CN2009801593410A CN200980159341A CN102438601A CN 102438601 A CN102438601 A CN 102438601A CN 2009801593410 A CN2009801593410 A CN 2009801593410A CN 200980159341 A CN200980159341 A CN 200980159341A CN 102438601 A CN102438601 A CN 102438601A
- Authority
- CN
- China
- Prior art keywords
- preparation
- ammonium salt
- skin
- compositions
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 97
- 239000003139 biocide Substances 0.000 claims abstract description 40
- 239000000758 substrate Substances 0.000 claims abstract description 19
- 230000005686 electrostatic field Effects 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 7
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 86
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 78
- 238000002360 preparation method Methods 0.000 claims description 54
- 230000003115 biocidal effect Effects 0.000 claims description 42
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 28
- 239000002562 thickening agent Substances 0.000 claims description 27
- 239000003995 emulsifying agent Substances 0.000 claims description 21
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 19
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 19
- 230000007062 hydrolysis Effects 0.000 claims description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims description 18
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 17
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 17
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 17
- 241000209140 Triticum Species 0.000 claims description 16
- 235000021307 Triticum Nutrition 0.000 claims description 16
- 230000002421 anti-septic effect Effects 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 16
- -1 Tristerin Chemical compound 0.000 claims description 15
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 14
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 13
- 102000011782 Keratins Human genes 0.000 claims description 13
- 108010076876 Keratins Proteins 0.000 claims description 13
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 13
- 150000001768 cations Chemical class 0.000 claims description 13
- 239000000080 wetting agent Substances 0.000 claims description 13
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 12
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 12
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 12
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 12
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 229960005323 phenoxyethanol Drugs 0.000 claims description 12
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 10
- 230000003068 static effect Effects 0.000 claims description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 230000002939 deleterious effect Effects 0.000 claims description 7
- 230000009849 deactivation Effects 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000004902 Softening Agent Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 210000002850 nasal mucosa Anatomy 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229960002163 hydrogen peroxide Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims 14
- 239000010409 thin film Substances 0.000 claims 8
- 239000010408 film Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 abstract description 8
- 238000009472 formulation Methods 0.000 abstract description 4
- 239000013022 formulation composition Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 230000000840 anti-viral effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 241000725681 Swine influenza virus Species 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 10
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 229920001083 polybutene Polymers 0.000 description 7
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 6
- 206010064097 avian influenza Diseases 0.000 description 6
- 229960002788 cetrimonium chloride Drugs 0.000 description 6
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 240000002853 Nelumbo nucifera Species 0.000 description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 5
- 229920006243 acrylic copolymer Polymers 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003344 environmental pollutant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000005497 microtitration Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 102000005714 Keratin-2 Human genes 0.000 description 3
- 108010070520 Keratin-2 Proteins 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 3
- 229940093541 dicetylphosphate Drugs 0.000 description 3
- 231100000719 pollutant Toxicity 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000003863 ammonium salts Chemical group 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- WTOOLIQYCQJDBG-BJILWQEISA-N but-1-ene;(e)-but-2-ene Chemical compound CCC=C.C\C=C\C WTOOLIQYCQJDBG-BJILWQEISA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- QSPIWLSLJAVCNC-UHFFFAOYSA-N 14-methylpentadecyl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C QSPIWLSLJAVCNC-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000005713 Keratin-1 Human genes 0.000 description 1
- 108010070514 Keratin-1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- RPSBVJXBTXEJJG-LURNZOHQSA-N alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)O1 RPSBVJXBTXEJJG-LURNZOHQSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Products and methods for reducing the risk of inhalation of harmful substances by applying a formulation composition to a substrate or skin in close proximity to one or more nostrils. The formulation, when applied, generates an electrostatic field having a charge. The electrostatic field attracts airborne particles of opposite charge to the substrate in close proximity to the substrate near the skin, and the biocides cause the microbial hazard in contact with the substrate or skin to become smaller.
Description
Cross reference with related application
A) the application's my rights and interests and priority of the non-temporary patent application serial number 12/467,271 of the unsettled U.S. of requiring to submit on May 16th, 2009, it incorporates this paper with its integral body into way of reference.
B) the application's my rights and interests and priority of unsettled international application no PCT/US09/44755 of requiring to submit on May 20th, 2009, it incorporates this paper with its integral body into way of reference.
Invention field
The present invention relates to resist typically the field of protective compsn of attack of attack and various microorganisms that gets into various stimulus object and the noxious substance of health through respiratory tract and/or nasal mucosa.The invention still further relates to and comprise that so far exploitation is used for limiting antiviral, antibacterium and the antimicrobial product and the method for use that airborne contaminant flow into the product of nasal meatus through produce electrostatic field in contiguous zone around nasal meatus (nasal passage).This reduces airborne contaminant inflow nasal meatus through catching pollutant and stoping them to get into health.In the present invention, the pollutant of virus, antibacterial and other detrimental microorganisms or poisonous granule are caught and kept comprising to the nose application product of these static electrification lotuses, makes their inactivations and make them harmless on vitro skin.
Background of invention
Nasal meatus and nasal mucosa are as the health inlet point of various nontoxic and noxious substances.The immune system of health is with reflex response, and for example cough and sneeze respond some harmless relatively stimulus object of nasal meatus and respiratory tract.This only introduces stimulus object in the environment again.Yet when stimulus object comprises microorganism, particularly in vivo when the breeding and the microorganism of propagating through cough and sneeze, other people possibility is infected.When a people felt that cough or sneeze arrive, he only covered his nose and face.Yet if that people is communicable, so this action can play a role to preventing that other people are also infected hardly.In addition, it also is extreme inefficient using toilet paper or handkerchief to be used for this purpose.This has limited the protection individual and has avoided infected or infect other people.
Processing prevents that other means that suck deleterious or the pungent or the vehicle of infection from comprising that the zone face cover is to filter out these stimulus object.The example is simple anti-dust respirator, generally can find in hard ware store or medication suppliers shop.Yet, even if they also are insufficient and inefficient.In a lot of places, in influenza season, people can see that much human wears these anti-dust respirators (dust mask) in public places.Present known anti-dust respirator is invalid.Another instance of this prophylactic methods is canister respirator (gas mask), and it is than anti-dust respirator effective percentage more.But, for micro-and submicroscopic microorganism, even canister respirator neither be high efficiency.In addition, they are extremely heavy and generally can not in normal daily routines, use.
Such as US6,844,005 patent described can external application to the nostril near and attract if not the compositions of the static electrification lotus of the material of the oppositely charged that like this then can be inhaled into.Yet those compositionss have produced the electrostatic field of the material that helps to filter out oppositely charged simply.Though the behavior can provide the particulate appropriate protection to passive suction, the fact that they suffer is that they can not handle the granule that oneself has the inherent mode that overcomes electrostatic force fully, for example active microorganism in air flow.In addition; Near the behavior that the nostril, has the people of those electrostatic compositions can be enough to make disagreeable granule or biology to leave; Particularly for example blow or the situation of wiping nose under, make that being caught fixed granule by foregoing can be moved out of, discharge again and be inhaled into.
Goal of the invention
Therefore, an object of the present invention is to being applied to perimeter around the nostril and/or inner or provide near near the compositions the source of release and can catch granule and method of microorganism and compositions at the edge in nostril slightly.
Another object of the present invention is to have fixing one section time and do not shifted out the ability that gets in the air flow once more.
Another object of the present invention provides and can be applied near near the peripheral region outside source of release or in the nostril and/or inner at the edge in nostril slightly, and with deactivation, kill or make the thing that has been combined catch the compositions harmless with fixed microorganism.
Another object of the present invention provide can be applied to filter substrate (filter substrate) with the seizure that improves substrate and immobilized particles and microorganism and while deactivation, kill or the compositions of the ability that feasible microorganism of being caught is harmless.Such filtration substrate can be placed near suck the path skin extremely near the place, near so particulate source of release, apart from the inspirator one segment distance is arranged simultaneously, perhaps the two has concurrently
Another object of the present invention provides and a kind ofly prophylactically prevents or reduce the infectious risk of the vehicle of infection in fact and do not utilize the method for the antiviral agent and/or the antibacterial agent of absorption.
Obtain after the benefit of present disclosure, other purposes of the present invention will be tangible to those skilled in the art.In all purposes mentioned above, the defective of the prior art of before mentioning is overcome by training centre of the present invention.
Summary of the invention
Of the present invention these are against expectation realized through the compositions that in water base or non-water base preparation, has the static electrification lotus of at least a polymeric quaternary ammonium compound with other purposes; Said compositions produces electrostatic field when being administered to the surface; Make gas at the oppositely charged of near surface carry granule (comprising microorganism) and caught by static, fixing on it and by a kind of or more kinds of microorganism of catching like this be neutralized, kill, deactivation and make it harmless.
Detailed Description Of The Invention
The present invention relates to comprise that use limits antimicrobial, antiviral/antibacterial product and the method that airborne contaminant flow into the product in the nasal meatus through producing electrostatic field in the zone that is close to or centers on nasal meatus.In addition, in the present invention, the nose application product of these static electrification lotuses is used to fixedly comprise the harmful or deleterious particulate pollutant of microorganism, virus, antibacterial and other in external, and makes them harmless.
The appearance of anthrax has been drawn and has been avoided sucking the notion that gas carries micro-or inferior micro-pollutant.The intent of the present invention is before the material such as the element/toxin/stimulus object of anthrax spore, human coronary virus, smallpox virus, influenza virus, bird flu virus, swine influenza virus, rhinovirus and other biological or chemical etc. gets into nasal meatus, filters them and makes them harmless.
It is chief reason of human breathing disease that gas carries microorganism, causes the pathogen infection of allergy, asthma and respiratory tract.It also is pathophorous important media that gas carries fungal spore.Respiratory disorder causes a lot of death, and is the reason that receives very big concern.In sneeze, millions of minimum water and mucus at full speed are discharged from.These contain virion and/or antibacterial.This is that several kinds of diseases are carried the approach that granule is propagated through sucking gas, as follows:
Because the disease that the environment granule causes includes but not limited to as follows:
。
In order to realize the present invention; Prepared preparation with at least a poly quaternary ammonium compound; Such chemical compound can be individually or jointly on its surface of using or produce electrostatic field on every side; Said surface comprises such as skin, textile (fabric and non-woven) and crust, such as the surface of floor, wall, wood, metal, plastics, glass etc.
Preparation generally is water base, but can comprise the employed nonaqueous solvent compatible with its application surface of using with other formulation components.Preferably, preparation is an aqueous formulation.Except poly quaternary ammonium compound (being also referred to as quaternary ammonium thickening agent or polymeric quaternary ammonium compound in the back literary composition), compositions comprises biocide (biocidic agent) at least.In addition, said composition can contain but not require and contains various thickening agents, gellant, spice, coloring agent, softening agent, wetting agent, and with other general suitable components of other compatible of end-use applications and said preparation.Therefore; Be intended to be applied to and be used as user and filter the present composition on the filtration substrate of the face shield that extra lining is arranged between the substrate and can utilize and to contact inconsistent material with skin direct; Though by the mode that is not intended to the reaction that contact causes between compositions and the skin, all components are preferred with the compatibility of directly using to skin as restriction.
Preparation of the present invention comprises:
Water,
At least a quaternary ammonium thickening agent,
Antiseptic,
Regulator,
Emulsifying agent,
Biocide and
Nertralizer (being also referred to as the pH regulator agent in the back literary composition), it is added into adjustment and realization scope at 5.0 to 6.8 pH.
Can also include but not limited to following combination:
Surfactant,
Thickening agent,
Softening agent,
Wetting agent and
Binding agent.
In the exemplary embodiment of such preparation, the quaternary ammonium thickening agent can include but not limited at least a in following:
Polyquaternary ammonium salt (Polyquaternium)-10
Polyquaternary ammonium salt-22
Polyquaternary ammonium salt-67
Polyquaternary ammonium salt-70
Polyquaternary ammonium salt-72
Polyquaternary ammonium salt-88
Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin
Hydroxyproyl Trimethyl ammonium wheat protein
The amount of quaternary ammonium thickening agent is preferably 0.5-30 wt%, more preferably 7-20 wt%.
Benzalkonium chloride (benzalkonium chloride) also can be brought into play same function, but it still is cation reagent and biocide.The other biological kill agent that can be used is lysine hydrochloride and hydrogen peroxide.
The biocide total amount is preferably 0.25-10 wt% in the compositions, and more preferably 0.25-6 wt% most preferably is 1-5 wt%.
In the exemplary embodiment of this type of preparation, emulsifying agent can include but not limited at least a in following:
Hexadecanol (it also can be used as thickening agent)
Cetearyl alcohol (Cetearyl Alcohol)
Tristerin (Glyceryl Stearate)
Cetearyl alcohol polyoxyethylenated alcohol-20 (Ceteareth-20)
The PEG-40 stearate
DCP (Dicetyl Phosphate)
Ceteth-10 phosphate ester (Ceteth-10 Phosphate)
The amount of emulsifying agent is preferably 0.3-5 wt%, more preferably 0.5-4 wt%.In this scope, can obtain the good hydrogel that is used to use.
In the exemplary embodiment of this type of preparation, softening agent can be but be not limited to mountain Yu acid different cetyl (Isocetyl Behenate).Thickening agent can be but be not limited to hexadecanol or stearyl alcohol.
In the exemplary embodiment of this type of preparation, antiseptic can include but not limited at least a in following:
Phenoxyethanol;
Methyl parahydroxybenzoate;
Butyl p-hydroxybenzoate;
Ethylparaben;
Propyl p-hydroxybenzoate;
P-Hydroxybenzoic acid isobutyl ester.
In compositions of the present invention, water is solvent and has the function as wetting agent.The content of water is preferably 30-90 wt% in the compositions, more preferably 35-75 wt%.
The instance of finding effective typical formulation is shown in the following table.Provide percentage ratio by weight.
Table 1
| Composition | Percentage range | Function |
| Water | 62% - 80% | Solvent, humidizer |
| Gluconic acid lactone, sodium benzoate | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator |
| Polyquaternary ammonium salt-67 | 3% - 6% | Regulator |
| Octoxinol-9 | 2% - 5% | Surfactant |
| Polyquaternary ammonium salt-72 | 6% -10% | Regulator |
| Polyquaternary ammonium salt-70 dipropylene glycol | 0.5%-1% | Regulator |
| The different cetyl of mountain Yu acid | 4%-6% | Softening agent |
| Stearyl alcohol | 1% - 3% | Thickening agent |
| Hexadecanol | 0.25% - 1% | Thickening agent |
| Cetearyl alcohol polyoxyethylenated alcohol-20, PEG-40 stearate, cetearyl alcohol | 1% -2% | Emulsifying agent |
| Water, hydrolysis algin | 0.5%-1.5% | Regulator |
| Hydrolyzed soybean protein | 0.25%-1% | Regulator |
Table 2
| Composition | Percentage range | Function |
| Water | 72% - 88% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Polyquaternary ammonium salt-67 | 3% - 6% | Regulator, quaternary ammonium |
| Nonoxynolum-10 | 2% - 4% | Surfactant |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 0.5%-2% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 0.5%-2% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% -4% | Regulator, quaternary ammonium |
| Cetearyl alcohol, tristerin emulsifying agent, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 1 % - 4% | Emulsifying agent |
| Cetearyl alcohol, DCP, ceteth-10 phosphate ester | 0.5% | Emulsifying agent |
| Benzalkonium chloride | 0.25%-1% | Cation reagent, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.01% - 0.05% | Nertralizer |
Table 3
| Composition | Percentage range | Function |
| Water | 67% - 87% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Polyquaternary ammonium salt-67 | 3%-7% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 3%-7% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 1% -4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% -4% | Regulator, quaternary ammonium |
| Hexadecanol | 1.5% -2.5% | Thickening agent |
| Cetearyl alcohol, glycerol PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 1%-4% | Emulsifying agent |
| Benzalkonium chloride | 0.25% -1% | Cation reagent, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.025%-0.075% | Nertralizer |
Table 4
| Composition | Percentage range | Function |
| Water | 71%-83% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Polyquaternary ammonium salt-67 | 4% - 6% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 4% - 6% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 2%-4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% - 3% | Regulator, quaternary ammonium |
| Hexadecanol | 2% | Thickening agent |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 1% - 3.5% | Emulsifying agent |
| Benzalkonium chloride | 0.25% -1% | Cation reagent ，Quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.025%-0.075% | Nertralizer |
Table 5
| Composition | Percentage range | Function |
| Water | 73% - 85% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Polyquaternary ammonium salt-67 | 2% - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 4% - 6% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 2% - 4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% - 3% | Regulator, quaternary ammonium |
| Hexadecanol | 2% | Thickening agent |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 1% - 3% | Emulsifying agent |
| Benzalkonium chloride | 0.25% -1% | Cation reagent, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.05% - 0.75% | Nertralizer |
Table 6
| Composition | Percentage range | Function |
| Water | 69% - 85% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Polyquaternary ammonium salt-10 | 0.25% - 0.85% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-67 | 1.5%-3.5% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 4% - 6% | Regulator, quaternary ammonium |
| Hexadecanol | 1% - 3% | Thickening agent |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 2%-4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-22 | 1% - 3% | Regulator, quaternary ammonium |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 1 % - 3% | Emulsifying agent |
| Benzalkonium chloride | 0.25% -1% | Regulator, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.05% - 0.75% | Nertralizer |
Table 7
| Composition | Percentage range | Function |
| Water | 67% - 86% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Polyquaternary ammonium salt-10 | 1 % - 4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-67 | 1 % - 4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 0.5%-1.5% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 0.5% -1.5% | Regulator, quaternary ammonium |
| Microcare Quat CTC 30 | 1 % - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1 % - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-22 | 1 % - 3% | Regulator, quaternary ammonium |
| Hexadecanol | 3% - 5% | Thickening agent |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 2% - 3% | Emulsifying agent |
| Benzalkonium chloride | 0.25%-1% | Regulator, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.05% - 0.1% | Nertralizer |
Table 8
| Composition | Percentage range | Function |
| Water | 58% - 74% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Glycerol | 10% | Wetting agent |
| Acetin/acrylic copolymer | 1% | Regulator, wetting agent |
| Polyquaternary ammonium salt-10 | 1 % - 4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-67 | 1% -3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 0.5% -1.5% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 0.5% -1.5% | Regulator, quaternary ammonium |
| Cetrimonium chloride | 1% - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-22 | 1% - 3% | Regulator, quaternary ammonium |
| Hexadecanol | 4% | Thickening agent |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 2% - 3% | Emulsifying agent |
| Polybutene | 4% | Binding agent |
| Benzalkonium chloride | 0.25%-1% | Regulator, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.05% - 0.1% | Nertralizer |
Table 9
| Composition | Percentage range | Function |
| Water | 54% - 73% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Glycerol | 8% | Wetting agent |
| Acetin/acrylic copolymer | 1% | Regulator, wetting agent |
| Polyquaternary ammonium salt-10 | 1% -4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-67 | 1% -4% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 0.5% - 2% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 0.5%-2% | Regulator, quaternary ammonium |
| Cetrimonium chloride | 1 % - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1% - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-22 | 1% - 3% | Regulator, quaternary ammonium |
| Hexadecanol | 4% | Thickening agent |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 2%-3% | Emulsifying agent |
| Polybutene | 3%-4% | Binding agent |
| Benzalkonium chloride | 0.25% -1% | Regulator, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.05% - 0.1% | Nertralizer |
Table 10
| Composition | Percentage range | Function |
| Water | 52% - 71% | Solvent, humidizer |
| Phenoxyethanol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, ethylparaben, p-Hydroxybenzoic acid isobutyl ester | 1% | Antiseptic |
| Lysine hydrochloride | 1% | Regulator, biocide |
| Glycerol | 9% | Wetting agent |
| Acetin/acrylic copolymer | 1% | Regulator, wetting agent |
| Polyquaternary ammonium salt-10 | 1% -3.5% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-67 | 1 % - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 0.5%-2% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 0.5% - 2% | Regulator, quaternary ammonium |
| Cetrimonium chloride | 1 % - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1 % - 3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-22 | 1 % - 3% | Regulator, quaternary ammonium |
| Hexadecanol | 4% | Thickening agent |
| Cetearyl alcohol, tristerin, PEG-40 stearate, cetearyl alcohol polyoxyethylenated alcohol-20 | 1 % - 4% | Emulsifying agent |
| Polybutene | 5% - 6% | Binding agent |
| Benzalkonium chloride | 0.25% - 1% | Regulator, quaternary ammonium, biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1% | Regulator, quaternary ammonium |
| Sodium hydroxide | 0.05% - 0.1% | Nertralizer |
Table 11
| Composition | Percentage range | Function |
| Water | 35%-75% | Solvent, humidizer |
| Phenonip | 0.5-1.5% | Antiseptic |
| Lysine hydrochloride | 0.5 -1.5% | Biocide, regulator |
| Glycerol | 8-12% | Wetting agent |
| Acetin/acrylic copolymer | 0.5-1.5% | Regulator, wetting agent |
| Polyquaternary ammonium salt-10 | 1%-3.5% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-67 | 1 %-3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-72 | 0.5%-2% | Regulator, quaternary ammonium |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 0.5%-2% | Regulator, quaternary ammonium |
| Cetrimonium chloride | 1 %-3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-88 | 1 %-3% | Regulator, quaternary ammonium |
| Polyquaternary ammonium salt-22 | 1 %-3% | Regulator, quaternary ammonium |
| Hexadecanol | 3-5% | Thickening agent |
| Lipomulse Luxe | 1%-4% | Emulsifying agent |
| Polybutene | 4%-7% | Binding agent |
| 50% benzalkonium chloride | 0.25-1% | Biocide, quaternary ammonium, regulator |
| 35% aqueous hydrogen peroxide solution | 0%-8.4% | Biocide |
| Hydroxyproyl Trimethyl ammonium wheat protein | 0.5-1.5% | Regulator, quaternary ammonium |
| 5% NaOH solution | 0-1.5% | Nertralizer |
For example, the preparation of table 11 comprises the cationic polymer of 8 kinds of scheduled volumes.Yet, only need contain any or more kinds of in these 8 kinds, and always need not add all these 8 kinds.
The preparation of the representative multiple embodiments of the present invention that all are described in table 1-11 is operated with the disclosed mode of this paper.Same result can realize through the percentage ratio that changes active and non-active ingredient.The percentage ratio that changes active component influences the effectiveness of preparation.The percentage ratio that changes non-active ingredient influences the concordance of preparation.Those skilled in the art can realize the result who expects and not need undo experimentation through change composition and their amount.
[using the method for antiviral prepared product]
Antiviral prepared product of the present invention (hereinafter is also referred to as antiviral composition) can be used for the various embodiments of following illustration.For example, it can ointment, the form of cream, gel, pulpous state agent, powder agent, lotion, spraying, liniment, viscosity transdermal patches, paster prepared product, aerosol, vanishing cream, liquid, Emulsion or suspensoid uses.Particularly, its quilt (1) usefulness finger, swab etc. directly are applied near the skin the nostril, and (2) are used to contain in the middle of the mask form of the filtration substrate of having used this prepared product, or (3) are applied to wall, base plate, ceiling etc.
Can regulate the preparation of antiviral composition according to the target of using suitably.For directly being applied to skin, for example, consider skin irritation etc., then the water content of compositions is provided with higherly, and the concentration of biocide etc. then is provided with lower.On the other hand; For being used as mask etc.,, therefore preferably that the biocide concentration setting is higher owing to more often directly not contacting with skin; And the water content after handling preferably is provided with lower, thereby makes air permeable through having used the filtration substrate of said composition.When not contacting with the people, such as wall etc., the viscosity of may command coating composition then, and can be provided with higherly in the compositions of being used such as the effective ingredient amount of biocide etc., wait to accomplish effectively and apply thereby can use spraying.
Embodiment
Below through reference embodiment 1-3 illustrated in detail the present invention as the specific embodiment of table 11 preparation, it can not be considered to limitation of the present invention.
The compositions that [product embodiments] the present invention produces embodiment can make through conventional method, comprises continuous and discrete heating and cooling step between 35 ℃-85 ℃, one after the other each composition is added to the water, and dissolves and disperses this composition.Prepared hydrogel composition has pH 5.0-6.8 at 30 ℃, suitably it is cooled to room temperature then, waits to be stored in the suitable containers.
Table 12 shown embodiment 1 (compositions S1), embodiment 2 (compositions S2) and embodiment 3 (compositions S3) antiviral agent become to be grouped into.
Table 12
| Component *4 | Embodiment 1 (S1) | Embodiment 2 (S2) | Embodiment 3 (S3) |
| Water | 55 g | 55 g | 55 g |
| Phenonip | 1 g | 1 g | 1 g |
| Lysine hydrochloride | 1 g | 1 g | 1 g |
| Glycerol | 10 g | 10 g | 10 g |
| Acetin/acrylic copolymer | 1 g | 1 g | 1 g |
| Polyquaternary ammonium salt-10 | 2.25 g | 2.25 g | 2.25 g |
| Polyquaternary ammonium salt-67 | 2 g | 2 g | 2 g |
| Polyquaternary ammonium salt-72 | 1.25 g | 1.25 g | 1.25 g |
| Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin | 1.25 g | 1.25 g | 1.25 g |
| Cetrimonium chloride | 2 g | 2 g | 2 g |
| Polyquaternary ammonium salt-88 | 2 g | 2 g | 2 g |
| Polyquaternary ammonium salt-22 | 2 g | 2 g | 2 g |
| Hydroxyproyl Trimethyl ammonium wheat protein | 1 g | 1 g | 1 g |
| Hexadecanol | 4 g | 4 g | 4 g |
| Lipomulse Luxe | 2.5 g | 2.5 g | 2.5 g |
| Indopol H100 (polybutene) | 3.1 g | 3.1 g | 3.1 g |
| Indopol H1500 (polybutene) | 2.4 g | 2.4 g | 2.4 g |
| 50% benzalkonium chloride | 0.3 g | 0.3 g | 0.3 g |
| 35% aqueous hydrogen peroxide solution | 0 | 5.7 | 8.6 |
| 5% NaOH solution | 0.75 g | 0.75 g | 0.75 g |
| Altogether | 95 g | 100 g | 103 g |
| The water yield *1 | 59 wt% | 59 wt% | 56 wt% |
| Cation dosage *2 | 14.4 wt% | 13.8 wt% | 13.3 wt% |
| Biocidal dosage *3 | 1.2 wt% | 3.2 wt% | 4.0 wt% |
* 1: the water in the aqueous hydrogen peroxide solution and the total amount of water
* 2: the total amount of polyquaternary ammonium salt, cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin and Hydroxyproyl Trimethyl ammonium wheat protein
* 3: the total amount of lysine hydrochloride, benzalkonium chloride and hydrogen peroxide
* 4: component is explained: Phenonip (trade (brand) name; Produce by Clariant UK Ltd.; The mixture of metagin in phenoxyethanol contains methyl parahydroxybenzoate, ethylparaben, butyl p-hydroxybenzoate, propyl p-hydroxybenzoate, p-Hydroxybenzoic acid isobutyl ester as metagin); (acetin/acrylic acid) copolymer (LUBRAJEL PF (trade (brand) name) is produced by United Guardian Inc.); Polyquaternary ammonium salt-10 (UCARE Polymer JR 400 (trade (brand) name) is produced by Amerchol Corporation); Polyquaternary ammonium salt-67 (SoftCat Polymer SX1300H (trade (brand) name) is produced by Amerchol Corporation); Polyquaternary ammonium salt-72 (MIRUSTYLE CP (trade (brand) name) is produced by Croda Inc.); Cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin (Croquat WKP (trade (brand) name) is produced by Croda Inc.); Cetrimonium chloride (MicroCare Quat CTC 30 (trade (brand) name) is produced by Thor Sarl Inc.); Polyquaternary ammonium salt-88 (Colaquat PDQ (trade (brand) name) is produced by Colonial Chemical Inc.); Polyquaternary ammonium salt-22 (Merquat 280 (trade (brand) name) is produced by Nalco Company); Emulsifying agent (Lipomulse Luxe (trade (brand) name) is produced by Lipo Chemicals Inc., and Lipomulse Luxe is the mixture of cetearyl alcohol, tristerin, PEG-40 stearate and cetearyl alcohol polyoxyethylenated alcohol-20); Polybutene (INDOPOL H 100 (trade (brand) name), INDOPOL H 1500 (trade (brand) name) are produced by INEOS Oligomers).
[antiviral properties assessment]
Assessed the antiviral properties of the invention described above example composition.
Test I. the antiviral effect of assessment embodiment 1-3 compositions resisiting influenza virus
(a) Test Virus
Use swine influenza virus (A/Osaka) and had the influenza virus (A/New Caledonia) of H1N1 chain.
Use the viral infection mdck cell, and (DMEM, NISSUI PHARMACEUTICAL CO. cultivated 3 days, and temperature is 34 ℃ in the Eagle culture medium of the Dulbecco improvement that is supplemented with 2.5 μ g/mL purification of trypsin in LTD.).The centrifugal culture medium of 1500 g 10 minutes.Reclaim cell and-80 ℃ of preservations.Use mdck cell and measure virus titer, and be shown as cell infection unit (CIU)/ml through IiT.
(b) test sample book
Embodiment 1 compositions (S1), embodiment 3 compositionss (S3) and contrast (C1)
(contrast: α 2,6-sialyllactose amine polymer (α 2,6-sialyllactosamine polymer) (6 '-SLN) 20 mg/mL)
(c) method of testing
(1) mdck cell is layered on 96 orifice plates, overnight incubation is to form cellular layer at the bottom of the hole.
(2) concentration of above-mentioned test sample book (S1, S3, C1) with 1 mg/mL is dissolved in phosphate buffered saline (PBS) (PBS) solution.
(3) two kinds of viral formulations prepared from solutions with swine influenza virus (A/Osaka) and influenza virus (A/New Caledonia) are 4.0x10
5CIU/mL, the 50 μ L of each mix with test sample book with it, and 25 ℃ of reactions 0.5 hour.
(4) remove cell culture medium through suction from each hole, the reactant mixture of 50 each test sample book of μ L with virus joined on the cellular layer in 2 holes, and at 5% CO
2Allow to be adsorbed onto on it 0.5 hour at 37 ℃ in the incubator.
(5) DMEM culture medium (150 μ L) is joined in each hole, at 5% CO
2In the incubator 37 ℃ of further culture mix 12 hours.
(6) remove culture medium through suction from each hole, and with 1% paraformaldehyde PBS solution fixed cell 1 hour.
(7) further handle cell 15 minutes with 1% Triton X-100, and use the PBS solution washing.
(8) through the immunofluorescence antibody method infected cell that dyes, count positive cell with fluorescence microscope.The antibody of each virus infected cell of being used to dye is identical with being used for the antibody that cell titer measures.
(d) test result
Embodiment 1 (compositions S1), embodiment 3 (compositions S3) and contrast (C1) have been tested, to confirm to observe the dilution ratio scope that virus suppresses effect.The result is shown in table 13.Contrast (C1) does not show that virus suppresses effect.
Table 13
Demonstrate the almost dilution ratio of 100% virus inhibition effect
| Viral species | Compositions S1 | Compositions S3 |
| Swine influenza virus (A/Osaka) | 1/128 | 1/256 |
| Influenza virus (A/New Caledonia) | 1/256 | 1/512 |
(numerical value in the table 13 is dilution ratio 1/n, and wherein bigger n shows that higher virus suppresses effect.)。
(e) test I brief summary
The compositions S3 that table 13 has disclosed compositions S1 and the embodiment 3 of the embodiment of the invention 1 has the good antiviral properties of anti-swine flu virus (A/Osaka) and influenza virus (A/New Caledonia).
Test I I. assessment is to the ERC group virus's on the artificial skin the effect of killing the virus
Assessed the kill the virus effect of embodiment 1-3 (compositions S1, S2 and S3) to the ERC group virus on the artificial skin.
(a) Test Virus
Used the ERC group virus.In the MRC-5 cell, cultivate and titration virus.In 1 ml aliquot, store virus-80 ℃ of preservations.Using the same day, take out a five equilibrium, thaw, and place on ice until using in experiment.
(b) cell culture
As the indicating clone that infects in the method for testing, said cell line shows cytopathic effect (CPE) after the ERC group virus infects with MRC-5 cell line.As needs, in disposable tissue culture flasks and 96 hole microtitration plates, keep cell, and use as monolayer.Testing the same day, observe cell and have suitable cell integrity, and be suitable for titration of virus.At 37 ℃ of cultured cells.
(c) cell culture medium
Cultured cell on the minimum minimal medium of the Eagle that contains penicillin 150 IU/mL, streptomycin 150 μ g/mL, neomycin 50 μ g/mL, ciprofloxacin 10 μ g/mL and amphotericin B 1.5 μ g/mL.
(d) method of testing
(d1) test substances preparation
Test composition S1, S2 and S3 have gel-like consistency when macroscopy, need not dilution and use.
(d2) dermal matrix preparation
Before using, through in the humid atmosphere that sterilely is placed on 87% relative humidity 16-18 hour, thus aquation VITRO-SKIN
TMUsing the same day, from VITRO-SKIN
TMSterilely downcut some about 1 cm on the sheet
2Sheet, and 6 skins are placed aseptic 6 orifice plates, every hole a slice.
(d3) method
The pieces of skin of prehydration is transferred in 6 orifice plates every hole a slice.Use the compositions of 20 μ L forward on 5 (1 to No. 5) each thick surface.With finger tip compositions is coated on the pieces of skin equably.The 6th skin (No. 6) is as positive control (only having virus, no compositions).Apply 20 μ L rhinovirus toward this each of 6.Apply the virus of being used by means of the microbionation ring.Behind each interval (table 14), 3% Carnis Bovis seu Bubali cream-0.05M glycine buffer (each sheet uses 0.9 ml buffer) of using pH 7.2 eluting virus on the pieces of skin.At once make 10 times of serial dilutions of eluate, and be inoculated in the cell monolayer (every hole 0.1 ml) that is based upon in the 96 hole microtitration plates, each diluent 4 hole.The non-infected cells contrast is then only inoculated with test media.Containing 5% CO
2Humid atmosphere at the cell of 32 ℃ of incubations inoculation.Check cell one time following every day at optical microscope, check the appearance of CPE.Behind the incubation 6 days, obtain final CPE reading, calculate virus titer through the Karber method.The result is as shown in table 14.
(d4) virus control
No. 6 sheets have wherein only been used virus as virus control, but do not use compositions.This is used for confirming the input titre of virus.
(e) result
Table 14
Test composition S1, S2 and the anti-ERC group virus's of S3 effect
* this result is the meansigma methods of 3 experiments.
1. after contact (exposures) time of 15 minutes, compositions S2 and S3 confirmed to be directed against the ERC group virus above 98% the effect of killing the virus.
2. after contact (exposures) time of 30 minutes, compositions S2 and S3 confirmed to be directed against the ERC group virus above 99% the effect of killing the virus.
Test I II. assessment is to the effect of killing the virus of swine influenza virus (SIV) on the artificial skin and bird flu virus (AIV)
Assessed the effect of killing the virus of embodiment 2 (compositions S2) and embodiment 3 (compositions S3) to swine influenza virus (SIV) on the artificial skin and bird flu virus (AIV)
(a) Test Virus
The H1N1 hypotype of swine influenza virus (SIV) and the H7N2 hypotype of bird flu virus (AIV) have been used.In mdck cell, cultivate and titration virus.In 1 ml aliquot, store virus-80 ℃ of preservations.Using the same day, take out a five equilibrium, thaw, and place on ice until using in experiment.
(b) cell culture
As the indicating clone that infects in the method for testing, said cell line shows cytopathic effect (CPE) after SIV and AIV infection with MDCK (Madin-Darby dog kidney) cell line.As needs, in disposable tissue culture flasks and 96 hole microtitration plates, keep cell, and use as monolayer.Testing the same day, observe cell and have suitable cell integrity, and be suitable for titration of virus.
(c) cell culture medium
Cultured cell on the minimum minimal medium of the Eagle that contains penicillin 150 IU/mL, streptomycin 150 μ g/mL, neomycin 50 μ g/mL, ciprofloxacin 10 μ g/mL and amphotericin B 1.5 μ g/mL.
(d) method of testing
(d1) test substances preparation
Test composition S2 and S3 have gel-like consistency when macroscopy, need not dilution and use.
(d2) dermal matrix preparation
Before using, through in the humid atmosphere that sterilely is placed on 87% relative humidity 16-18 hour, thus aquation VITRO-SKIN
TMUsing the same day, from VITRO-SKIN
TMSterilely downcut some about 1 cm on the sheet
2Sheet, and 6 skins are placed aseptic 6 orifice plates, every hole a slice.
(d3) method
The pieces of skin of prehydration is transferred in 6 orifice plates every hole a slice.Use the compositions of 20 μ L forward on 5 (1 to No. 5) each thick surface.With finger tip compositions is coated on the pieces of skin equably.The 6th skin (No. 6) is as positive control (only having virus, no compositions).Apply 20 μ L SIV or AIV toward this each of 6.Apply the virus of being used by means of the microbionation ring.Behind each interval (table 15), 3% Carnis Bovis seu Bubali cream-0.05M glycine buffer (each sheet uses 0.9 ml buffer) of using pH 7.2 eluting virus on the pieces of skin.At once make 10 times of serial dilutions of eluate, and be inoculated in the cell monolayer (every hole 0.1 ml) that is based upon in the 96 hole microtitration plates, each diluent 4 hole.The non-infected cells contrast is then only inoculated with test media.Containing 5% CO
2Humid atmosphere at the cell of 35-37 ℃ of incubation inoculation.Check cell one time following every day at optical microscope, check the appearance of CPE.Behind the incubation 96 hours, obtain final CPE reading, calculate virus titer through the Karber method.The result is as shown in Tble 15.
(d4) virus control
No. 6 sheets have wherein only been used virus as virus control, but do not use compositions.This is used for confirming the input titre of virus.
(e) result
Table 15
The effect of anti-AIV of test composition S2 and S3 and SIV
* this result is the meansigma methods of 3 experiments.
(f) test I II conclusion
1. after contact (exposures) time of 15 minutes, the compositions S2 of the embodiment of the invention and S3 confirmed to H1N1 swine flue (SIV) virus and H7N2 bird flu (AIV) viral above 98% the effect of killing the virus.
2. after contact (exposures) time of 30 minutes, compositions S2 and S3 confirmed to H1N1 swine flue (SIV) virus and H7N2 bird flu (AIV) viral above 99% the effect of killing the virus.
As test I is explained, antiviral composition of the present invention even also demonstrate antiviral properties 128 to 512 times the time when dilution, and obviously have extremely effectively antiviral properties.And the appearance of being explained like test I I and test I II when the compositions of antiviral agent of the present invention is applied to skin, can be inactivated with the virus of the contact skin of being used, and makes it harmless at short notice.
Through associating biocide and polymeric quaternary ammonium compound, the present invention has realized the effect of killing the virus that is difficult to realize through biocide separately.In other words, antiviral composition of the present invention provides significant effect through the coexistence of polymeric quaternary ammonium compound and biocide, and wherein it can not only show sterilizing function, also shows the function of extremely effectively killing the virus.
Industrial applicibility
Compositions of the present invention not only can be through directly being applied to skin; Especially near the skin the nostril; Thereby be used for antibiotic or antiviral; But also through being applied to fiber product etc., and the fiber product of using this coating is isolated tent or the like, thereby is used for antibiotic or anti-viral uses as mask, health product, diaper, medicated clothing, towel, socks, glove, various filter, airborne disease.In addition, also can be through directly applying at wall, the end of sterilizing room or aseptic box, and further wall, floor, ceiling, door handle, furniture, instrument etc., thus said composition is used for the domestic use of said composition.
Claims (34)
1. be used for static and prevent that the deleterious particle thing go into to infect individual method through snuffing, wherein preparation is applied to the skin or the tissue of said individual nasal meatus with form of film, and said method comprises:
A) the said particulate matter of electrostatic attraction to said thin film;
B) adhesion through the said thin film of adjustment so that said adhesion of film to said skin or tissue, and the cohesiveness through adjusting said preparation to be providing enough impermeability to said thin film, thereby said particulate matter is fixed on correct position; And
C) make the harmless at least a composition of said particulate matter make said particulate matter deactivation through adding.
2. reduce the method for the risk that sucks the deleterious particle material, comprise and use compositions that wherein said substrate is used in substrate or skin:
A) source of release of the extremely approaching said particulate matter in ground in 0 to 150 mm scope;
B) to one or more nostril;
And wherein:
C) said skin is in the zone at least one nostril, perhaps at least one nostril;
D) said compositions is when being used; Produce in said substrate or said skin or on every side electrostatic field with electric charge, make said electrostatic field from extremely near said substrate pass said substrate or air near said skin place process in will have an opposite charges particulate matter be attracted to said substrate;
E) said particulate matter is fixed on the sufficiently long time of correct position, so that microorganism that wherein contain and that contact with said skin or said substrate is than with which the harm of microorganism is not little.
3. be used for static and prevent that the deleterious particle thing go into to infect individual preparation through snuffing, wherein said preparation is applied to the skin or the tissue of individual nasal meatus with form of film, and said preparation comprises:
A) be used for through adjusting said thin film adhesion so that said adhesion of film to skin or tissue, and the cohesiveness through adjusting said preparation to be providing enough impermeability to said thin film, thereby said particulate matter is fixed on the device of correct position; And,
B) be used for making the harmless at least a composition of said particulate matter make the device of said particulate matter deactivation through adding.
4. one kind is used for static and prevents that the deleterious particle thing go into to infect individual preparation through snuffing; Wherein said preparation is applied to the skin or the tissue of individual nasal meatus with form of film; Said preparation comprises at least a cation reagent and at least a biocide, and wherein said preparation is used the back:
A) the said particulate matter of electrostatic attraction is in said thin film;
B) adhesion through the said thin film of adjustment so that said adhesion of film to skin or tissue, and the cohesiveness through adjusting said preparation to be providing enough impermeability to said thin film, thereby said particulate matter is fixed on correct position; And,
C) make said particulate matter deactivation, and make said particulate matter harmless.
5. the preparation of claim 4, wherein said at least a cation reagent is a polymeric quaternary ammonium compound.
6. the preparation of claim 5, wherein said at least a polymeric quaternary ammonium compound is taken from the group of being made up of following:
Polyquaternary ammonium salt-10,
Polyquaternary ammonium salt-22,
Polyquaternary ammonium salt-67,
Polyquaternary ammonium salt-70,
Polyquaternary ammonium salt-72 and
Polyquaternary ammonium salt-88.
7. the preparation of claim 4, wherein said at least a cation reagent is cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin or Hydroxyproyl Trimethyl ammonium wheat protein.
8. the preparation of claim 4, wherein said at least a cation reagent is a benzalkonium chloride.
9. the preparation of claim 4, wherein said at least a biocide is benzalkonium chloride or lysine hydrochloride.
10. be used for static and prevent that the deleterious particle thing go into to infect individual preparation through snuffing, wherein said preparation is applied to the skin or the tissue of individual nasal meatus with form of film, and said preparation comprises:
A) at least a biocide and
B) at least a quaternary ammonium thickening agent.
11. the preparation of claim 10, wherein said at least a biocide is benzalkonium chloride or lysine hydrochloride.
12. the preparation of claim 10, wherein said at least a quaternary ammonium thickening agent is taken from the group of being made up of following:
Polyquaternary ammonium salt-10,
Polyquaternary ammonium salt-22,
Polyquaternary ammonium salt-67,
Polyquaternary ammonium salt-70,
Polyquaternary ammonium salt-72 and
Polyquaternary ammonium salt-88.
13. the preparation of claim 10, wherein said at least a quaternary ammonium thickening agent are cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin or Hydroxyproyl Trimethyl ammonium wheat protein.
14. the preparation of claim 10, wherein said at least a quaternary ammonium thickening agent is a benzalkonium chloride.
15. the described preparation of claim 10 also comprises:
A) water,
B) antiseptic,
C) regulator and
D) emulsifying agent.
16. the preparation of claim 15 also comprises the scope that is added into adjustment pH at 5.0 to 6. 8 nertralizer.
17. the preparation of claim 15, also comprises surfactant.
18. the preparation of claim 15 also comprises thickening agent.
19. the preparation of claim 15 also comprises softening agent.
20. the preparation of claim 15 also comprises wetting agent.
21. the preparation of claim 15 also comprises binding agent.
22. the preparation of claim 15, wherein said antiseptic is taken from the group of being made up of following:
Phenoxyethanol,
Methyl parahydroxybenzoate,
Butyl p-hydroxybenzoate,
Ethylparaben and
P-Hydroxybenzoic acid isobutyl ester.
23. the preparation of claim 15, wherein said emulsifying agent is taken from the group of being made up of following:
Hexadecanol,
Cetearyl alcohol,
Tristerin,
Cetearyl alcohol polyoxyethylenated alcohol-20,
The PEG-40 stearate,
DCP,
Ceteth-10 phosphate ester.
24. the preparation of claim 18, wherein said thickening agent are hexadecanol or stearyl alcohol.
25. the preparation of claim 15, wherein:
A) scope of the amount of water is by weight from 54% to 90%;
B) scope of the amount of said quaternary ammonium thickening agent is by weight from 0.5% to 5.0%;
C) scope of the amount of biocide is by weight from 0.25% to 2%;
D) scope of the amount of emulsifying agent is by weight from 0.5% to 4%.
26. comprise the antiviral agent compositions of cation reagent, biocide and water.
27. the compositions of claim 26, wherein said cation reagent is a polymeric quaternary ammonium compound.
28. the compositions of claim 27, wherein said polymeric quaternary ammonium compound are selected from polyquaternary ammonium salt-10, polyquaternary ammonium salt-22, polyquaternary ammonium salt-67, polyquaternary ammonium salt-70, polyquaternary ammonium salt-72, polyquaternary ammonium salt-88, cocoyl Dimethyl Ammonium hydroxypropyl hydrolysis of keratin, Hydroxyproyl Trimethyl ammonium wheat protein and combination thereof.
29. each compositions of claim 26-28, wherein said biocide is selected from benzalkonium chloride, lysine hydrochloride, hydrogen peroxide and combination thereof.
30. each compositions of claim 26-29 also comprises and is selected from least a in antiseptic, nertralizer, skin soft agent, wetting agent, binding agent, regulator and the thickening agent.
31. the compositions of claim 30 also comprises emulsifying agent, and with the form of hydrogel.
32. the compositions of claim 26, wherein
A) amount of water is 30-90 wt%;
B) amount of cation reagent is 0.5-30 wt%, and
C) amount of biocide is 0.25-10 wt%.
33. each compositions of claim 26-32, it is the form of ointment, cream, gel, pulpous state agent, powder agent, lotion, spraying, liniment, viscosity transdermal patches, paster prepared product, aerosol, vanishing cream, liquid, Emulsion or suspensoid.
34. the compositions of claim 33 is used to be applied to nostril, near skin or the nasal mucosa in nostril.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/467271 | 2009-05-16 | ||
| US12/467,271 US8163802B2 (en) | 2008-07-07 | 2009-05-16 | Electrostatically charged multi-acting nasal application, product, and method |
| PCT/US2009/044755 WO2010005637A2 (en) | 2008-07-07 | 2009-05-20 | Electrostatically charged multi-acting nasal application, product, and method |
| USPCT/US2009/044755 | 2009-05-20 | ||
| PCT/US2009/069689 WO2010134942A1 (en) | 2009-05-16 | 2009-12-29 | Electrostatically charged multi-acting nasal application, product and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102438601A true CN102438601A (en) | 2012-05-02 |
Family
ID=43126425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801593410A Withdrawn CN102438601A (en) | 2009-05-16 | 2009-12-29 | Electrostatically charged multifunctional nasal applications, products and methods |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2012526857A (en) |
| CN (1) | CN102438601A (en) |
| WO (1) | WO2010134942A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087645A (en) * | 1993-06-24 | 2019-08-02 | 舒泰公司 | The nose application method and product of static electrification lotus for micro-filtration |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8515525B2 (en) * | 2011-08-16 | 2013-08-20 | Women's Imaging Solutions Enterprises Llc | Skin adhesive agent for mammography procedures |
| KR101561735B1 (en) | 2013-09-25 | 2015-10-19 | 주식회사 엘지화학 | Method for electrode assembly |
| EP4205755A1 (en) | 2018-07-20 | 2023-07-05 | Shiseido Company, Limited | Virus inactivating agent |
| CN111265473A (en) * | 2018-12-04 | 2020-06-12 | 南京从一医药科技有限公司 | Dual-functional nose protection gel with foreign matter blocking and sterilization effects |
| JP7333207B2 (en) * | 2019-06-11 | 2023-08-24 | 花王株式会社 | antibacterial composition |
| PE20231183A1 (en) * | 2020-09-25 | 2023-08-11 | Posi Visionary Solutions Llp | PHARMACEUTICAL COMPOSITION WITH ELECTROSTATIC CHARGE AND METHOD OF OBTAINING |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161790A1 (en) * | 2002-02-25 | 2003-08-28 | Trutek Corp. | Electrostatically charged nasal application product with increased strength |
| US20040071757A1 (en) * | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468488A (en) * | 1993-06-24 | 1995-11-21 | Wahi; Ashok L. | Electrostatically charged nasal application product and method |
| US20020006961A1 (en) * | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| US6531142B1 (en) * | 1999-08-18 | 2003-03-11 | The Procter & Gamble Company | Stable, electrostatically sprayable topical compositions |
| JP4870431B2 (en) * | 2003-08-20 | 2012-02-08 | ワヒ、アショック、エル． | Enhanced electrostatic charge nasal products |
| US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
| US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US10918618B2 (en) * | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
| EA012555B1 (en) * | 2005-05-31 | 2009-10-30 | Дбв Текноложи | Support having electrostatic properties for allergen screening and applicator for same |
| US20070243237A1 (en) * | 2006-04-14 | 2007-10-18 | Mazen Khaled | Antimicrobial thin film coating and method of forming the same |
| KR101602516B1 (en) * | 2008-07-07 | 2016-03-10 | 트루텍 코프. | Electrostatically charged multi-acting nasal application, product, and method |
-
2009
- 2009-12-29 CN CN2009801593410A patent/CN102438601A/en not_active Withdrawn
- 2009-12-29 JP JP2012511801A patent/JP2012526857A/en not_active Withdrawn
- 2009-12-29 WO PCT/US2009/069689 patent/WO2010134942A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040071757A1 (en) * | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
| US20030161790A1 (en) * | 2002-02-25 | 2003-08-28 | Trutek Corp. | Electrostatically charged nasal application product with increased strength |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087645A (en) * | 1993-06-24 | 2019-08-02 | 舒泰公司 | The nose application method and product of static electrification lotus for micro-filtration |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012526857A (en) | 2012-11-01 |
| WO2010134942A1 (en) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102438601A (en) | Electrostatically charged multifunctional nasal applications, products and methods | |
| US20100136072A1 (en) | Polymeric Coatings that Inactivate Viruses and Bacteria | |
| Ochiai et al. | Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells | |
| US9119814B2 (en) | Composition for prevention of influenza viral infection comprising sumac extract, air filter comprising the same and air cleaning device comprising the filter | |
| JP2022500361A (en) | Anti-pathogenic compositions and methods thereof | |
| CN111686125A (en) | Application of carrageenan in resisting novel coronavirus | |
| CN102089039B (en) | Electrostatically charged mask filter products and method for increased filtration efficiency | |
| KR20170033925A (en) | Spray compositions having antiviral efficacy and antibacterial agent | |
| JP5189291B2 (en) | Viricidal activity of cetylpyridinium chloride. | |
| US20240124617A1 (en) | Compositions comprising exopolysaccharides and uses thereof | |
| AU2009269074B2 (en) | Electrostatically charged multi-acting nasal application, product, and method | |
| CN111408733A (en) | Antibacterial and antiviral nano silver colloidal solution and preparation method and application thereof | |
| CN102088964B (en) | Electrostatically charged multi-acting nasal application product | |
| US8110605B2 (en) | Compound for inactivating viruses and bacteria and method of making same | |
| CA2756115A1 (en) | Antiseptic compositions for the treatment of infections | |
| HK1170179A (en) | Electrostatically charged multi-acting nasal application, product and method | |
| EP1042551A1 (en) | Materials for virus capture | |
| GB2275194A (en) | Plant Extract Disinfectant | |
| CN101094896A (en) | Novel uses of calcium hydroxide | |
| KR20120024730A (en) | Electrostatically charged multi-acting nasal application, product and method | |
| Larson | Antiviral polymeric drugs and surface coatings | |
| TWI847301B (en) | Antiviral agent, method for imparting antiviral property, article having antiviral property, antibacterial agent, article having antibacterial property, antifungal agent, and article having antifungal property | |
| US20240180154A1 (en) | Liquid spray formulation | |
| Han | Utilizing Salt-Coated Polypropylene Fabrics in Face Masks and Covers to Combat Respiratory Disease Transmission | |
| Ghosh et al. | Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1170179 Country of ref document: HK |
|
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20120502 |